Table 1.
Baseline characteristics of patients with prostate cancer (n = 55).
| Variable | Total (n = 55) | ADT (n = 33) | ADT + RT (n = 22) | p-value |
|---|---|---|---|---|
| Age (yr) | 76.3 ± 5.1 | 77.1 ± 4.4 | 75.0 ± 5.8 | 0.131 |
| Height (cm) | 164.8 ± 5.2 | 165.0 ± 4.5 | 164.5 ± 6.2 | 0.674 |
| Weight (kg) | 63.5 ± 8.5 | 63.4 ± 7.4 | 63.6 ± 10.0 | 0.912 |
| Comorbidity, any | 39 (70.9) | 24 (72.7) | 15 (68.2) | 0.718 |
| Living place | 0.273 | |||
| Urban | 25 (45.5) | 13 (39.4) | 12 (54.5) | |
| Rural | 30 (54.5) | 20 (60.6) | 10 (45.5) | |
| Education level | ||||
| Less than high school | 21 (38.2) | 13 (39.4) | 8 (36.4) | 0.563 |
| High school and above | 5 (9.1) | 4 (12.1) | 1 (4.5) | |
| Unknown | 29 (52.7) | 16 (48.5) | 13 (59.1) | |
| Economic activity | ||||
| Active | 15 (27.3) | 7 (21.2) | 8 (36.4) | 0.221 |
| None | 40 (72.7) | 26 (78.8) | 14 (63.6) | |
| Marital status | ||||
| Married | 35 (63.6) | 22 (66.7) | 13 (59.1) | 0.571 |
| Unmarried | 20 (36.4) | 11 (33.3) | 9 (40.9) | |
| Smoking | ||||
| Current | 8 (14.5) | 3 (9.1) | 5 (22.7) | 0.295 |
| Past | 19 (34.5) | 11 (33.3) | 8 (36.4) | |
| None | 28 (50.9) | 19 (57.6) | 9 (40.9) | |
| Drinking | ||||
| Current | 8 (14.5) | 4 (12.1) | 4 (18.2) | 0.394 |
| Past | 29 (52.7) | 18 (54.5) | 11 (50.0) | |
| None | 18 (32.7) | 11 (33.3) | 7 (31.8) | |
| Clinical T stage | ||||
| 2 | 8 (14.5) | 6 (18.2) | 2 (9.1) | 0.356 |
| 3 | 42 (76.4) | 23 (69.7) | 19 (86.4) | |
| 4 | 5 (9.1) | 4 (12.1) | 1 (4.5) | |
| Clinical N stage | ||||
| 0 | 49 (89.1) | 28 (84.8) | 21 (95.5) | 0.221 |
| 1 | 6 (10.9) | 5 (15.2) | 1 (4.5) | |
| Clinical M stage | ||||
| 0 | 48 (87.3) | 27 (81.8) | 21 (95.5) | 0.141 |
| 1b | 7 (12.7) | 6 (18.2) | 1 (4.5) | |
| Biopsy Gleason score | ||||
| 6 | 7 (12.7) | 4 (12.1) | 3 (13.6) | 0.939 |
| 7 | 19 (34.5) | 12 (36.4) | 7 (31.8) | |
| ≥ 8 | 29 (52.7) | 17 (51.5) | 12 (54.5) | |
| Tumor type | ||||
| Localized high risk | 45 (81.8) | 25 (75.8) | 20 (90.9) | 0.157 |
| Mets | 10 (18.2) | 8 (24.2) | 2 (9.1) | |
| PSA (ng/mL) | 35.7 ± 45.8 | 30.8 ± 45.2 | 43.2 ± 46.7 | 0.329 |
| Karnofsky performance status | ||||
| 100 | 50 (90.9) | 28 (84.8) | 22 (100) | 0.159 |
| 90 | 3 (5.5) | 3 (9.1) | 0 (0) | |
| 80 | 2 (3.6) | 2 (6.1) | 0 (0) | |
ADT = androgen deprivation therapy; RT = radiation therapy; PSA = prostate-specific antigen; Mets = Metastasis.